Amgen: Q3 EPS up 6%

(CercleFinance.com) - Amgen has reported Q3 2023 non-GAAP EPS that is up 6% at $4.
96, despite a non-GAAP operating margin that slipped 0.5% to 52%, while revenue increased by 4% to $6.9bn.

The biotech group's product sales rose 5%, boosted by 11% growth in volumes supported by double-digit growth for its Blincyto, Evenity, Repatha and Nplate products.

For FY 2023, Amgen now expects non-GAAP EPS of $18.20 to $18.80 (up from $17.80 to $18.80), and revenues of $28bn to $28.4bn (up from $26.6bn to $27.4bn).


Copyright (c) 2023 CercleFinance.com. All rights reserved.